{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:43:12Z","timestamp":1790152992569,"version":"4.0.1"},"reference-count":73,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["20-05736S"],"award-info":[{"award-number":["20-05736S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000759"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000759"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Therapeutic agents with novel mechanisms of action are urgently needed to counter the emergence of drug-resistant infections. Several decades of research into proteases of disease agents have revealed enzymes well suited for target-based drug development. Among them are the three recently validated proteolytic targets: proteasomes of the malarial parasite Plasmodium falciparum, aspartyl proteases of P. falciparum (plasmepsins) and the Sars-CoV-2 viral proteases. Despite some unfulfilled expectations over previous decades, the three reviewed targets clearly demonstrate that selective protease inhibitors provide effective therapeutic solutions for the two most impacting infectious diseases nowadays\u2014malaria and COVID-19.<\/jats:p>","DOI":"10.3390\/ijms22115762","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T11:33:20Z","timestamp":1622201600000},"page":"5762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Protease Inhibition\u2014An Established Strategy to Combat Infectious Diseases"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-9435","authenticated-orcid":false,"given":"Daniel","family":"Sojka","sequence":"first","affiliation":[{"name":"Biology Centre, Institute of Parasitology, Academy of Sciences of the Czech Republic, Brani\u0161ovsk\u00e1 1160\/31, CZ-37005 \u010cesk\u00e9 Bud\u011bjovice, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"\u0160nebergerov\u00e1","sequence":"additional","affiliation":[{"name":"Biology Centre, Institute of Parasitology, Academy of Sciences of the Czech Republic, Brani\u0161ovsk\u00e1 1160\/31, CZ-37005 \u010cesk\u00e9 Bud\u011bjovice, Czech Republic"},{"name":"Faculty of Science, University of South Bohemia in \u010cesk\u00e9 Bud\u011bjovice, Brani\u0161ovsk\u00e1 1760c, CZ-37005 \u010cesk\u00e9 Bud\u011bjovice, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00efse","family":"Robbertse","sequence":"additional","affiliation":[{"name":"Biology Centre, Institute of Parasitology, Academy of Sciences of the Czech Republic, Brani\u0161ovsk\u00e1 1160\/31, CZ-37005 \u010cesk\u00e9 Bud\u011bjovice, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"McKerrow, J.H. (2005). Designing Drugs for Parasitic Diseases of the Developing World. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020210"},{"key":"ref_2","unstructured":"Despommier, D.D., Griffin, D.O., Gwadz, R.W., Hotez, P.J., and Knirsch, C.A. (2019). Parasitic Diseases, Parasites without Borders, Inc.. [7th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Young, K.M., Corrin, T., Wilhelm, B., Uhland, C., Greig, J., Mascarenhas, M., and Waddell, L.A. (2019). Zoonotic Babesia: A scoping review of the global evidence. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226781"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1074\/jbc.TM118.004156","article-title":"Proteases: History, discovery, and roles in health and disease","volume":"294","author":"Bond","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/pro.3948","article-title":"How to use the MEROPS database and website to help understand peptidase specificity","volume":"30","author":"Rawlings","year":"2021","journal-title":"Protein Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Barrett, A.J., Rawlings, N.D., Salvesen, G., and Woessner, J.F. (2013). Handbook of Proteolytic Enzymes Introduction, Academic Press. [3rd ed.].","DOI":"10.1016\/B978-0-12-382219-2.00838-3"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrd3053","article-title":"Emerging principles in protease-based drug discovery","volume":"9","author":"Drag","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nchembio837","article-title":"Drug discovery and development for neglected parasitic diseases","volume":"2","author":"Renslo","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1146\/annurev.pathol.1.110304.100151","article-title":"PROTEASES IN PARASITIC DISEASES","volume":"1","author":"McKerrow","year":"2006","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(95)90699-1","article-title":"Safety and activity of saquinavir in HIV infection","volume":"345","author":"Kitchen","year":"1995","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/INF.0b013e31827b1bd3","article-title":"Long-term Lopinavir\/Ritonavir Monotherapy in HIV-infected Children","volume":"32","author":"Kosalaraksa","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/978-1-4419-8414-2_7","article-title":"Cruzain: The path from target validation to the clinic","volume":"712","author":"Sajid","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"McKerrow, J.H. (2018). Update on drug development targeting parasite cysteine proteases. PLOS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0005850"},{"key":"ref_15","first-page":"1","article-title":"Gartner\u2019s hype cycle: A simple explanation","volume":"5","author":"Perez","year":"2018","journal-title":"Int. J. Comput. Optim."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-biochem-061516-044908","article-title":"Proteasomal and Autophagic Degradation Systems","volume":"86","author":"Dikic","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and Function of the 26S Proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"ref_19","first-page":"179","article-title":"Update on proteasome inhibitors in multiple myeloma","volume":"12","author":"Richardson","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/febs.14029","article-title":"Targeting proteasomes in infectious organisms to combat disease","volume":"284","author":"Jiang","year":"2017","journal-title":"FEBS J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1475-2875-7-187","article-title":"Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon","volume":"7","author":"Kreidenweiss","year":"2008","journal-title":"Malar. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1128\/AAC.42.10.2731","article-title":"Proteasome Inhibitors Block Development ofPlasmodium spp","volume":"42","author":"Gantt","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21344-8","article-title":"20S proteasomes secreted by the malaria parasite promote its growth","volume":"12","author":"Dekel","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-7-13","article-title":"Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B","volume":"7","author":"Reynolds","year":"2007","journal-title":"BMC Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e73530","DOI":"10.1371\/journal.pone.0073530","article-title":"Blocking Plasmodium falciparum Development via Dual Inhibition of Hemoglobin Degradation and the Ubiquitin Proteasome System by MG132","volume":"8","author":"Prasad","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chembiol.2012.09.019","article-title":"Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity","volume":"19","author":"Li","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13562","DOI":"10.1021\/ja507692y","article-title":"Identification of Potent and Selective Non-covalent Inhibitors of thePlasmodium falciparumProteasome","volume":"136","author":"Li","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.1021\/acs.jmedchem.8b01161","article-title":"Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome","volume":"61","author":"Xie","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.trsl.2018.04.007","article-title":"The proteasome as a target to combat malaria: Hits and misses","volume":"198","author":"Krishnan","year":"2018","journal-title":"Transl. Res."},{"key":"ref_30","first-page":"233","article-title":"Structure- and function-based design of Plasmodium-selective proteasome inhibitors","volume":"530","author":"Li","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1021\/acs.jmedchem.9b00363","article-title":"Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors","volume":"62","author":"Zhan","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1021\/acs.jmedchem.7b00671","article-title":"Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity","volume":"60","author":"LaMonte","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Stokes, B.H., Yoo, E., Murithi, J.M., Luth, M.R., Afanasyev, P., Da Fonseca, P.C.A., Winzeler, E.A., Ng, C.L., Bogyo, M., and Fidock, D.A. (2019). Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007722"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1600-0854.2007.00589.x","article-title":"A Family of Aspartic Proteases and a Novel, Dynamic and Cell-Cycle-Dependent Protease Localization in the Secretory Pathway of Toxoplasma gondii","volume":"8","author":"Shea","year":"2007","journal-title":"Traffic"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.pt.2016.05.015","article-title":"Parasite Cathepsin D-Like Peptidases and Their Relevance as Therapeutic Targets","volume":"32","author":"Sojka","year":"2016","journal-title":"Trends Parasitol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1074\/jbc.REV120.009309","article-title":"Malaria parasite plasmepsins: More than just plain old degradative pepsins","volume":"295","author":"Nasamu","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2174\/156802612799362959","article-title":"Recent advances in plasmepsin medicinal chemistry and implications for future antimalarial drug discovery efforts","volume":"12","author":"Meyers","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpara.2016.06.001","article-title":"Host cell remodelling in malaria parasites: A new pool of potential drug targets","volume":"47","author":"Gilson","year":"2017","journal-title":"Int. J. Parasitol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molbiopara.2005.05.015","article-title":"Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparum","volume":"143","author":"Klemba","year":"2005","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_40","first-page":"627","article-title":"An aspartyl protease directs malaria effector proteins to the host cell","volume":"463","author":"Boddey","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_41","first-page":"70","article-title":"Malaria parasite translocon structure and mechanism of effector export","volume":"561","author":"Ho","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.celrep.2019.11.073","article-title":"Inhibition of Plasmepsin V Activity Blocks Plasmodium falciparum Gametocytogenesis and Transmission to Mosquitoes","volume":"29","author":"Jennison","year":"2019","journal-title":"Cell Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1021\/jm500797g","article-title":"Transition State Mimetics of the Plasmodium Export Element are Potent Inhibitors of Plasmepsin V from P. falciparum and P. vivax","volume":"57","author":"Sleebs","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nsmb.3061","article-title":"Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes","volume":"22","author":"Hodder","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejmech.2018.05.022","article-title":"Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P 2 position of PEXEL peptidomimetics","volume":"154","author":"Nguyen","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7554\/eLife.27480","article-title":"A druggable secretory protein maturase of Toxoplasma essential for invasion and egress","volume":"6","author":"Dogga","year":"2017","journal-title":"eLife"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MOH.0000000000000334","article-title":"Molecular mechanisms that mediate invasion and egress of malaria parasites from red blood cells","volume":"24","author":"Alaganan","year":"2017","journal-title":"Curr. Opin. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ijpara.2012.04.005","article-title":"Plasmodium subtilisin-like protease 1 (SUB1): Insights into the active-site structure, specificity and function of a pan-malaria drug target","volume":"42","author":"Suarez","year":"2012","journal-title":"Int. J. Parasitol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7554\/eLife.61121","article-title":"The malaria parasite sheddase SUB2 governs host red blood cell membrane sealing at invasion","volume":"9","author":"Collins","year":"2020","journal-title":"eLife"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.chom.2020.02.005","article-title":"Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle","volume":"27","author":"Favuzza","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.aaf8675","article-title":"A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress","volume":"358","author":"Pino","year":"2017","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.aan1478","article-title":"Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion","volume":"358","author":"Nasamu","year":"2017","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"616341","DOI":"10.3389\/fmolb.2020.616341","article-title":"Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19","volume":"7","author":"Cui","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1021\/bi0504761","article-title":"Papain-Like Protease 2 (PLP2) from Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV): Expression, Purification, Characterization, and Inhibition","volume":"44","author":"Han","year":"2005","journal-title":"Biochemistry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ratia, K., Kilianski, A., Baez-Santos, Y.M., Baker, S.C., and Mesecar, A. (2014). Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating Activity of SARS-CoV Papain-Like Protease. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004113"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti\u2013COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e106275","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","article-title":"Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity","volume":"65","author":"Hoffmann","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"103289","DOI":"10.1016\/j.ebiom.2021.103289","article-title":"COVID19 therapeutics: Expanding the antiviral arsenal","volume":"66","author":"Gallagher","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_65","first-page":"1","article-title":"Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia","volume":"12","author":"Sakr","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gunst, J.D., Staerke, N.B., Pahus, M.H., Kristensen, L.H., Bodilsen, J., Lohse, N., Dalgaard, L.S., Br\u00f8nnum, D., Fr\u00f6bert, O., and H\u00f8nge, B. (2021). Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. EClinicalMedicine, 100849.","DOI":"10.1016\/j.eclinm.2021.100849"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"00754-20","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Mahoney, M., Damalanka, V.C., Tartell, M.A., Chung, D.H., Lourenco, A.L., Pwee, D., Mayer Bridwell, A.E., Hoffmann, M., Voss, J., and Karmakar, P. (2021). A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. bioRxiv.","DOI":"10.1101\/2021.05.06.442935"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/HIV.S79956","article-title":"HIV protease inhibitors: A review of molecular selectivity and toxicity","volume":"7","author":"Wang","year":"2015","journal-title":"HIV\/AIDS Res. Palliat. Care"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/toxres\/tfaa106","article-title":"A target safety assessment of the potential toxicological risks of targeting plasmepsin IX\/X for the treatment of malaria","volume":"10","author":"Barber","year":"2021","journal-title":"Toxicol. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/cbic.201200007","article-title":"The Carmaphycins: New Proteasome Inhibitors Exhibiting an \u03b1,\u03b2-Epoxyketone Warhead from a Marine Cyanobacterium","volume":"13","author":"Pereira","year":"2012","journal-title":"ChemBioChem"},{"key":"ref_72","unstructured":"Kumar, T.M., Rohini, K., James, N., Shanthi, V., and Ramanathan, K. (2021). Discovery of Potent Covid-19 Main Protease Inhibitors using Integrated Drug Repurposing Strategy. Biotechnol. Appl. Biochem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"16314","DOI":"10.1073\/pnas.1903330116","article-title":"Functional selection of protease inhibitory antibodies","volume":"116","author":"Lopez","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5762\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:28Z","timestamp":1760162968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":73,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijms22115762"],"URL":"https:\/\/doi.org\/10.3390\/ijms22115762","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}